Global AL Amyloidosis Epidemiology Forecast to 2030 – ResearchAndMarkets.com

Global AL Amyloidosis Epidemiology Forecast to 2030 – ResearchAndMarkets.com




Global AL Amyloidosis Epidemiology Forecast to 2030 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “AL Amyloidosis – Epidemiology Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.

This ‘AL Amyloidosis – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

AL Amyloidosis Disease Understanding

Amyloidosis refers to a group of complex diseases caused by protein misfolding and aggregation into highly ordered amyloid fibrils that deposit in tissues, resulting in progressive organ damage. A cross-B-sheet quaternary structure characterizes these amyloid fibrils. It is typically found in individuals with monoclonal gammopathy.

AL amyloidosis is characterized by the proliferation of clonal plasma cells. It causes the increased production of immunoglobulin light chains to become misfolded and aggregate into amyloid fibrils, leading to organ damage. As the amyloid builds up in an organ, nerve, or tissue, it gradually causes damage and affects their function. Each amyloidosis patient has a different pattern of amyloid deposition in their body. It often affects more than one organ, except the brain.

AL Amyloidosis Epidemiology

The AL amyloidosis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the Incident patient pool and their trends along with assumptions undertaken.

Key Findings

The total Incident cases of AL Amyloidosis patients in the 7MM will rise during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical and forecasted AL amyloidosis symptoms epidemiology segmented as the total incident cases of AL amyloidosis, Gender-specific cases of AL amyloidosis, and age-specific cases of AL amyloidosis. The report presents the incident scenario of AL amyloidosis symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Epidemiology of AL Amyloidosis

The epidemiology segment also provides the AL Amyloidosis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total Incident cases of AL Amyloidosis associated in 7MM countries were 8,550 in 2017.

  • As per the estimates, the United States has the largest incident population of AL amyloidosis.
  • In 2017, among the EU5 countries, Germany had the highest Incident cases of AL amyloidosis, followed by France. On the other hand, Spain had the lowest Incident cases, with 406 cases.

Key Topics Covered:

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 AL Amyloidosis: Market Overview at a Glance

5.1 Total Market Share (%) Distribution of AL Amyloidosis in 2017

5.2 Total Market Share (%) Distribution of AL Amyloidosis in 2030

6 AL Amyloidosis: Disease Overview

6.1 Introduction

6.2 Types of Amyloidosis

6.3 Etiology

6.4 Signs and Symptoms

6.5 Clinical Presentation

6.6 Pathophysiology

6.7 Prognosis

6.8 Diagnosis

6.8.1 Differential Diagnosis

6.8.2 Diagnostic guidelines

6.8.3 Diagnostic Algorithm

7 Epidemiology and Patient Population

7.1 Key Findings

8 7MM Epidemiology

8.1 Assumptions and rationale

8.2 Total cases of AL Amyloidosis in the 7MM

9 KOL Views

10 BIBLIOGRAPHY

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/4ml6wc

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900